Biotechs Partnering To Combine CRISPR Gene Editing With Stem Cells To Treat Diabetes.
September 18, 2018
Fortune (9/17, Mukherjee) reports CRISPR Therapeutics and ViaCyte are partnering to combine CRISPR gene editing with stem cells to treat type 1 diabetes. Recently, the companies agreed to an “initial deal...worth up to $25 million, including $15 million...